NeuroPace Inc.
NPCE | NASDAQ
$14.78
+$0.24 (+1.65%)
Sep 22, 2026, 1:23 PM ET · Market open
Company Profile
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Key Executives
| Name | Position |
|---|---|
| Joel D. Becker | Chief Executive Officer, President & Director |
| Patrick F. Williams | Chief Financial Officer |
| Amy Treadwell | Vice President of Human Resources |
| Chris Reese | Senior Vice President of Sales |
| Dylan John | Chief of Operations & Development |
| Julie Hsu | Vice President & Controller |
| Katie Keller | Vice President of Marketing |
| Leah Akin | General Counsel & Corporate Secretary |
| Martha J. Morrell | Chief Medical Officer |
| Scott R. Schaper | Head of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 04, 2026 | 4 | Filing |
| Sep 04, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 28, 2026 | 4 | Filing |
| Aug 28, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Jul 28, 2026 | 8-K | Current Report |
| Jun 25, 2026 | 4 | Filing |
| Jun 22, 2026 | 4 | Filing |
NeuroPace Inc.
| Country | United States |
| IPO Date | Apr 21, 2021 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 220 |
| CEO | Joel D. Becker |
Contact Details
455 North Bernardo Avenue Mountain View,
California 94043 United States
Stock Details
| Ticker Symbol | NPCE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001528287 |
| CUSIP Number | 641288105 |
| ISIN Number | US6412881053 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove NPCE